Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
JOINT Corp received an update to a major shareholder’s disclosure as Bandera Partners and its affiliates reported beneficial ownership of 3,937,296 shares of common stock, or about 26.5% of the shares outstanding as of November 3, 2025. All of these shares are held through Bandera Master Fund, with Bandera Partners and individuals Jefferson Gramm and Gregory Bylinsky sharing voting and dispositive power.
On January 5, 2026, Bandera entered into a Letter Agreement with JOINT Corp under which the company agreed to nominate Jefferson Gramm to its board of directors at the 2026 annual meeting and recommend that stockholders vote for his election. In return, Bandera agreed not to increase its ownership above the current 3,937,296 shares, other than any awards granted to Gramm as a director, until a termination date that falls between 30 days before the 2027 nomination deadline and January 21, 2027. The amendment also notes that the reporting persons have not traded JOINT Corp shares in the past 60 days.
The Joint Corp. (JYNT) director and 10% owner Charles E. Jobson reported open-market purchases of the company’s common stock. On 11/21/2025 he bought 10,000 shares at $8.50 per share, on 11/24/2025 he bought 4,680 shares at $8.36, and on 11/25/2025 he bought 2,081 shares at $8.43. After these transactions, he beneficially owned 1,592,027 JYNT shares held directly.
JOINT Corp (JYNT) disclosed an initial ownership report for investor Charles E. Jobson, who is identified as both a director and a 10% owner of the company. As of the reportable event on 11/11/2025, Jobson beneficially owned 1,575,266 shares of JOINT Corp common stock in direct form. The filing is a Form 3, which serves as the first statement of beneficial ownership when someone becomes an insider subject to reporting requirements.
The Joint Corp. reported Q3 2025 results showing modest top-line growth and a return to profitability. Total revenue was $13.38 million, up from $12.65 million a year ago, driven by higher royalty, franchise, advertising, and software fees as the business shifts toward franchising.
Income from continuing operations was $290,370 versus a loss of $414,383 last year, while discontinued operations contributed $564,639 as the company refranchises and exits company-run clinics. Net income was $855,009 compared with a net loss of $3.17 million in Q3 2024. For the nine months, revenue reached $39.73 million and net income was $1.92 million.
Cash and cash equivalents were $29.70 million at September 30, 2025, up from $25.05 million at year-end. The company repurchased $2.29 million of common stock during the quarter. The network ended the period with 884 franchised clinics and 78 company-owned or managed clinics, for 962 total. As of November 3, 2025, 14,866,192 common shares were outstanding.
The Joint Corp. (JYNT) entered a material definitive agreement to sell the assets of, and grant franchise rights to, 45 company-owned or managed clinics in Southern California to Elite Chiro Group for an aggregate purchase price of $4.5 million, subject to adjustments. The price includes $3,154,500 in cash and $1,345,500 in prorated franchise fees across 45 franchise agreements. Elite Chiro Group will pay a $100,000 non-refundable down payment for exclusivity, with the balance due at closing; if unpaid at closing, the balance will convert into a secured promissory note maturing 60 days from signing.
The transaction is expressly conditioned on assigning existing leases for at least 38 of the 45 clinics or executing specified management agreements, along with customary closing conditions. In connection with the deal, The Joint will acquire non-exclusive development rights for 10 clinics, with a $90,000 development fee. Separately, the Board authorized an additional $12.0 million under the stock repurchase program and extended it through November 4, 2027.
JOINT Corp (JYNT) entered a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank, N.A. on September 30, 2025. The amendment expressly consents to the company's refranchising of all company-owned or managed clinics and extends the maturity date of the company's revolving credit facility to August 31, 2027. The amendment includes customary representations, warranties, and conditions precedent. The filing notes the 2025 Amendment is attached as Exhibit 10.1 and that the short description provided is qualified in its entirety by the full amendment text.
TheJoint operates a rapidly expanded clinic network, growing from eight clinics in 2010 to 967 clinics in operation as of December 31, 2024 and again reporting 967 locations (franchised or company-owned/managed) as of June 30, 2025 across 42 states and D.C. The company’s model emphasizes low-cost, appointment-free chiropractic care with membership plans, charging a 7.0% royalty and a 2.0% national marketing fee on franchised clinics and collecting an initial franchise fee of $39,900. In 2023 management began a plan to refranchise or sell most company-owned clinics and in Q3 2024 expanded that plan to market the full portfolio in geographic clusters. Clinical visits average 15–20 minutes for new patients and 5–7 minutes for returning patients. The prospectus contains customary forward-looking statements and references filings incorporated by reference.
Form 144 notice for The Joint Corp. (JYNT) reports a proposed sale of 12,000 shares of common stock via Raymond James on 08/29/2025 with an aggregate market value of $127,920. The filing shows the 12,000 shares were acquired through RSU vesting on multiple dates between 08/07/2021 and 05/25/2024, and that the planned sale equals the total of those vested RSUs. The issuer's outstanding shares are listed as 15,340,000, and the filing also discloses a prior sale by the same person of 20,000 common shares on 08/22/2025 for gross proceeds of $215,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
The company disclosed the departure of its Chief Financial Officer, Mr. Singleton, whose role ceased effective June 9, 2025. The company and Mr. Singleton entered a separation agreement dated August 22, 2025 that includes a general release and a revocation period. If not revoked, the agreement provides Separation Benefits: a cash payment equal to six months of base salary, a cash payment for accumulated time off of $36,193.99, an additional cash payment of $15,000, reimbursement for accrued expenses per company policy, and payment of up to six months of COBRA health-insurance cost if elected. Outstanding equity awards will be governed by existing award agreements and plans and will not receive accelerated vesting under the Separation Agreement.
The filer submitted a Form 144 to notify a proposed sale of 20,000 common shares of The Joint Corp. (JYNT) through Raymond James & Associates on NASDAQ, with an aggregate market value of $215,000 and approximately 15,340,000 shares outstanding. The shares were acquired by the same person through two stock option exercises: 10,289 shares on 08/22/2025 and 9,711 shares on 08/25/2025, each paid in cash on the exercise dates. The filer reports no securities sold in the past three months. The form includes the routine certification that the seller is not aware of undisclosed material adverse information. Certain filer identification fields in the provided content are blank.